DOI: 10.1016/j.clnu.2023.06.027 Gualdiero, P., Ferrara, L., Ferrara, E., et al
How does tirzepatide's receptor target differ from semaglutide's
Another GLP-1 analogue, lixisenatide, was reported to prevent the acuteness of cardiovascular events in apolipoprotein E / insulin receptor substrate 2 +/ (APOE / irs2 +/ ) mice by reducing the size of AS plaques, increasing plaque stability, and promoting the conversion of macrophages to the anti-inflammatory M2 phenotype (129)
Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease): systematic review and meta-analysis
By 8 weeks, many individuals report losing 35% of their starting body weight